Universität zu Köln

Drzezga, Alexander, Altomare, Daniele ORCID: 0000-0003-1905-8993, Festari, Cristina ORCID: 0000-0003-3597-5097, Arbizu, Javier ORCID: 0000-0002-8370-5510, Orini, Stefania, Herholz, Karl, Nestor, Peter ORCID: 0000-0002-5860-5921, Agosta, Federica ORCID: 0000-0003-3121-4979, Bouwman, Femke, Nobili, Flavio ORCID: 0000-0001-9811-0897, Walker, Zuzana ORCID: 0000-0001-7346-8200, Frisoni, Giovanni Battista and Boccardi, Marina ORCID: 0000-0001-6744-8246 (2018). Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging, 45 (9). S. 1487 - 1497. NEW YORK: SPRINGER. ISSN 1619-7089

Full text not available from this repository.

Abstract

To assess the clinical utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of early signs of neurodegeneration in conditions of increased risk for Alzheimer's disease (AD) as defined by: subjective cognitive decline (SCD), evidence of cerebral amyloid-pathology, apolipoprotein E (APOE) epsilon 4-positive genotype, or autosomal dominant forms of AD (ADAD) in asymptomatic stages. A comprehensive literature search was conducted using the PICO model to extract evidence from relevant studies. An expert panel then voted using the Delphi method on three different diagnostic scenarios. The level of empirical study evidence for the use of FDG-PET to detect meaningful early signs of neurodegeneration was considered to be poor for ADAD and lacking for SCD and asymptomatic persons at risk, based on APOE epsilon 4-positive genotype or cerebral amyloid pathology. Consequently, and consistent with current diagnostic criteria, panelists decided not to recommend routine clinical use of FDG-PET in these situations and to currently mainly reserve it for research purposes. Currently, there is limited evidence on which to base recommendations regarding the clinical routine use of FDG-PET to detect diagnostically meaningful early signs of neurodegeneration in asymptomatic subjects with ADAD, with APOE epsilon 4-positive genotype, or with cerebral amyloid pathology, and in subjects with SCD. Future prospective studies are warranted and in part already ongoing, aiming to assess the added value of FDG-PET in this context beyond research applications.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Drzezga, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Altomare, Daniele UNSPECIFIED orcid.org/0000-0003-1905-8993 UNSPECIFIED Festari, Cristina UNSPECIFIED orcid.org/0000-0003-3597-5097 UNSPECIFIED Arbizu, Javier UNSPECIFIED orcid.org/0000-0002-8370-5510 UNSPECIFIED Orini, Stefania UNSPECIFIED UNSPECIFIED UNSPECIFIED Herholz, Karl UNSPECIFIED UNSPECIFIED UNSPECIFIED Nestor, Peter UNSPECIFIED orcid.org/0000-0002-5860-5921 UNSPECIFIED Agosta, Federica UNSPECIFIED orcid.org/0000-0003-3121-4979 UNSPECIFIED Bouwman, Femke UNSPECIFIED UNSPECIFIED UNSPECIFIED Nobili, Flavio UNSPECIFIED orcid.org/0000-0001-9811-0897 UNSPECIFIED Walker, Zuzana UNSPECIFIED orcid.org/0000-0001-7346-8200 UNSPECIFIED Frisoni, Giovanni Battista UNSPECIFIED UNSPECIFIED UNSPECIFIED Boccardi, Marina UNSPECIFIED orcid.org/0000-0001-6744-8246 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-180315
DOI:	10.1007/s00259-018-4032-1
Journal or Publication Title:	Eur. J. Nucl. Med. Mol. Imaging
Volume:	45
Number:	9
Page Range:	S. 1487 - 1497
Date:	2018
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1619-7089
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MILD COGNITIVE IMPAIRMENT; GLUCOSE-METABOLISM; MEMORY COMPLAINTS; OLDER-ADULTS; LONGITUDINAL ASSESSMENT; ELDERLY SUBJECTS; GENETIC RISK; HYPOMETABOLISM; DECLINE; BIOMARKER Multiple languages Radiology, Nuclear Medicine & Medical Imaging Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/18031